3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
24
Endocrine
24
Thoracic
6
Gynecologic
6
Gastrointestinal
3
CNS
3
Plasma cell
2
Other hematologic neoplasm
2
NET
2
Myeloid
2
Dermatologic
2
Sarcoma
1
Lymphoid
1
Genitourinary
1
Breast
1
Conditions
Multiple Myeloma
937
Lymphoma
113
Recurrence
93
Neoplasms, Plasma Cell
92
Lymphoma, Non-Hodgkin
68
Immunoglobulin Light-chain Amyloidosis
60
Hematologic Neoplasms
60
Neoplasms
54
Smoldering Multiple Myeloma
52
Leukemia, Myeloid, Acute
51
Leukemia
51
Myelodysplastic Syndromes
47
Leukemia, Lymphocytic, Chronic, B-Cell
45
Precursor Cell Lymphoblastic Leukemia-Lymphoma
38
Hodgkin Disease
38
Leukemia, Plasma Cell
27
Myeloproliferative Disorders
24
Breast Neoplasms
24
Monoclonal Gammopathy of Undetermined Significance
23
Lymphoma, Large B-Cell, Diffuse
23
Lymphoma, Mantle-Cell
22
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
22
Amyloidosis
22
Primary Myelofibrosis
21
Lymphoma, Follicular
21
Waldenstrom Macroglobulinemia
20
Ovarian Neoplasms
20
Lymphoma, B-Cell, Marginal Zone
17
Lymphoma, B-Cell
17
Colorectal Neoplasms
17
Interventions
trametinib
1
dabrafenib
1
cobimetinib
1
Vemurafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Thyroid Carcinoma, Anaplastic
×
Plasma cell
×
1 year
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled